Le Lézard
Classified in: Health
Subjects: TDS, TRI

MYR Pharma Completes Clinical Trial of Myrcludex B in Chronic Hepatitis Delta


BURGWEDEL, Germany, March 12, 2018 /PRNewswire/ -- MYR Pharma GmbH today announced the completion of its MYR 202 clinical trial, a Phase 2b study investigating Myrcludex B in chronic hepatitis Delta (HDV), the most severe form of viral hepatitis that currently has no satisfactory treatment options. A total of 120 subjects were enrolled into MYR 202 in 20 centers in Russia and Germany, which makes it the world's largest HDV clinical study. The results of the study will be presented at the General Session of the upcoming International Liver Congress, an annual meeting of the European Association for the Study of the Liver (EASL) in Paris, France on April 12, 2018.

"The positive results of the active therapy phase of this study were already presented at the AASLD meeting in Washington, DC in October 2017," said Alexander Alexandrov, MD, Chief Medical Officer of MYR Pharma. "The follow-up phase of this study is now completed. This is a very important milestone in the development of Myrcludex B under the PRIME scheme in Europe," he added.

"We appreciate that the EASL annual meeting organizers recognize the significance of the HDV medical problem and the importance of the results of this so far largest study with a novel compound in hepatitis Delta", said Heiner Wedemeyer, MD, Professor at Essen University Hospital and Chairman of MYR Pharma's Clinical Advisory Board.

About Myrcludex  B

Myrcludex B is a first-in-class entry inhibitor for the treatment of chronic hepatitis B (HBV) and its co-infection hepatitis Delta. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver. The drug has received Orphan Designation for treatment of HDV infection from the EMA and FDA, and PRIME scheme eligibility from the EMA. 

To find out more about Myrcludex B, visit http://myr-pharma.com/science/about-myrcludex-b.

About MYR Pharma

MYR Pharma GmbH is a German clinical stage biotechnology company focused on the development of drugs for the treatment of chronic hepatitis B and Delta virus infections. For more information, please visit http://myr-pharma.com.

Contact:  Alexey Eliseev, 1-617-953-0767

SOURCE MYR Pharma


These press releases may also interest you

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...



News published on and distributed by: